Results 61 to 70 of about 867,912 (295)

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Short Communications: Basic Sciences

RUHS Journal of Health Sciences, 2023
Postgraduate Students
doaj   +1 more source

Arjuna's recollections – Part III (or) an endocrine version of the “Motorcycle Diaries”

Indian Journal of Endocrinology and Metabolism, 2016
The ultimate dream of every young student stepping into the hallowed portals of a medical college is to achieve the holy grail of medical education, a DM seat. However, the real battle begins only after the DM seat is won.
V Sri Nagesh
doaj   +1 more source

Beyond postgraduate training [PDF]

Postgraduate Medical Journal, 1994
Wearenow looking beyond postgraduate training whichendswhenjunior doctors attain consultant status. Medical education isopen-ended. Itisa continuum whichextends fromundergraduate through postgraduate or vocational training to continuing medical education forcareer, orpermanent,grades.
openaire   +2 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Short Communications: Para Clinical Sciences

RUHS Journal of Health Sciences, 2023
Postgraduate Students
doaj   +1 more source

Naval Postgraduate School Commencement Ceremony / Class of September 2003 [PDF]

, 2003
Date of Commencement ceremony: 2003-09 ...
Naval Postgraduate School (U.S.)
core   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Short Communications: Clinical Sciences

RUHS Journal of Health Sciences, 2023
Postgraduate Students
doaj   +1 more source

Naval Postgraduate School Commencement Ceremony / Class of September 2012 [PDF]

, 2012
Date of Commencement ceremony: 2012-09 ...
Naval Postgraduate School (U.S.)
core